Free tool
FAERS Monitor: Dupixent
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761055 or its brand name (Dupixent, Dupilumab). Reports on generic versions are filed under their own applications.
Reports
518,489
Serious
57,042
11% of reports
Hospitalization
24,493
Death reported
2,351
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pruritus65,143
- dermatitis atopic48,270
- product use in unapproved indication44,555
- rash41,246
- injection site pain40,378
- drug ineffective32,504
- dry skin28,839
- eczema28,786
- product dose omission issue25,576
- condition aggravated21,742
- arthralgia20,813
- inappropriate schedule of product administration19,713
- accidental exposure to product18,392
- asthma17,440
- exposure via skin contact16,495
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 2 |
| 2016 | 7 |
| 2017 | 1,107 |
| 2018 | 7,626 |
| 2019 | 14,912 |
| 2020 | 20,259 |
| 2021 | 40,308 |
| 2022 | 58,512 |
| 2023 | 66,771 |
| 2024 | 88,410 |
| 2025 | 114,890 |
| 2026 | 105,685 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,535,670 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dermatitis atopicSignal | 48,270 | 423.6 | 410.9 | 1,744,448 |
| exposure via skin contactSignal | 16,495 | 69.2 | 67.4 | 403,966 |
| eczemaSignal | 28,786 | 48.3 | 47.5 | 602,365 |
| dry skinSignal | 28,839 | 10.9 | 10.8 | 204,656 |
| product use in unapproved indicationSignal | 44,555 | 8.7 | 8.6 | 250,983 |
| accidental exposure to productSignal | 18,392 | 8.6 | 8.5 | 101,900 |
| pruritusSignal | 65,143 | 8.1 | 8.0 | 341,624 |
| asthmaSignal | 17,440 | 7.2 | 7.1 | 79,448 |
| injection site painSignal | 40,378 | 6.0 | 5.9 | 148,174 |
| inappropriate schedule of product administrationSignal | 19,713 | 4.9 | 4.8 | 54,273 |
| rashSignal | 41,246 | 4.1 | 4.1 | 90,635 |
| product dose omission issueSignal | 25,576 | 3.8 | 3.7 | 48,174 |
| condition aggravatedSignal | 21,742 | 3.0 | 3.0 | 28,172 |
| arthralgiaSignal | 20,813 | 2.1 | 2.1 | 11,386 |
| drug ineffective | 32,504 | 1.0 | 1.0 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.